1. Scrip
  2. >>Business

December Sees Three Milestones For ViiV’s Pipeline

R&D Chief Outlines 2 FDA Filings, 1 Expected Approval

 
• By Sten Stovall

ViiV Healthcare’s R&D head Kimberly Smith tells Scrip December will see the advancement of three key HIV therapies.

HIV
ViiV is a specialist HIV company • Source: Shutterstock

ViiV Healthcare , the specialty HIV company owned by GlaxoSmithKline PLC, Pfizer Inc. and Shionogi & Co. Ltd. will achieve three important regulatory milestones in December that should lead to new products becoming available to different patient populations in 2020, the group’s head of R&D has told Scrip.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.